ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Clinical Outcomes of Patients with Portal Vein Tumor Thrombi after Living Donor Liver Transplantation

D. Kim

Surgery, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of

Meeting: 2019 American Transplant Congress

Abstract number: B334

Keywords: Graft survival, Hepatocellular carcinoma, Liver transplantation, Recurrence

Session Information

Date: Sunday, June 2, 2019

Session Name: Poster Session B: Liver: Living Donors and Partial Grafts

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • Surgical Technique and Outcomes of Portal Vein Reconstruction of Adult-to-Adult Living Donor Liver Transplantation Recipients with Portal Vein Thrombosis
  • Refinement of Non-Invasive Diagnostic Criteria to Differentiate Tumor from Bland Portal Vein Thrombosis Before Liver Transplant in Patients With Hepatocellular Carcinoma

*Purpose: Patient selection criteria for living donor liver transplantation(LDLT) with hepatocellular carcinoma are generally wider than those for deceased donor liver transplantation. It is widely accepted that LT should not be performed when a main portal vein tumor thrombus (PVTT) is present. The purpose of this study was to evaluate the feasibility of LDLT for treatment of patients with hepatocellular carcinoma and segmental PVTT.

*Methods: Between January 2005 and December 2016, we retrospectively analyzed 242 patients in a control group (n=184), a microvascular invasion (MVI) group (n=24), and a PVTT group (n=34). PVTT was diagnosed preoperatively when intrathrombus vascularity was evident in the arterial phases of imaging studies (CT or MRI) just before LT. And finally, PVTT was pathologically confirmed in the explant liver. A PVTT below the second-order branch was defined as segmental; a PVTT in the first-order branch was defined as lobar. To assess the risks associated with PVTT, we evaluated recurrence, the disease-free survival (DFS) rate, the overall survival (OS) rate, and various other factors based on the characteristics of patients and tumors.

*Results: Of the 242 patients, 5-year DFS and OS rates were 79.5% and 70.7%. A total of 34(14.0%) patients had PVTT, of whom 7 had lobar PVTT in first-order branches. The control, MVI, and PVTT groups significantly differed in terms of tumor morphology (maximal and total diameters) and biology (alpha-fetoprotein [AFP] and protein induced by vitamin K absence or antagonist II). The control, MVI, and PVTT groups significantly differed in terms of the recurrence, DFS, and OS rates. Especially, lobar PVTT reduced the 5-year DFS and OS rates to dismal and 14.3%, respectively, but segmental PVTT was associated with favorable 5-year DFS and OS rates (63.9% and 50.3%, respectively). We found no statistically significant difference in the DFS and OS rates of patients with MVI alone andsegmental PVTT alone. In patients in the segmental PVTT group with AFP levels of <100 ng/mL, the 5-year DFS and OS rates were 90.9% and 71.3%, respectively.

*Conclusions: Liver transplantation has become one of the most effective modalities by which to treat HCC. Lobar PVTT remains a contraindication for LT. However, the presence of segmental PVTT may be acceptable. To achieve better results, we recommend that the AFP level be considered such as the AFP level is <100 ng/mL when selecting patients with segmental PVTT.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kim D. Clinical Outcomes of Patients with Portal Vein Tumor Thrombi after Living Donor Liver Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-outcomes-of-patients-with-portal-vein-tumor-thrombi-after-living-donor-liver-transplantation/. Accessed February 27, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.